Dendritic Cell Tumor Fusion
Neuroectodermal Tumors
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Neuroectodermal Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide DNAtrix, Inc. | Phase 2 | B |
Epirubicin DNAtrix, Inc. | Phase 2 | B |
Pembrolizumab DNAtrix, Inc. | Phase 2 | B |
TASADENOTUREV DNAtrix, Inc. | Phase 2 | B |
Pralsetinib, trans- Hoffmann-La Roche | Phase 1/2 | CCC |
Interleukin-12 Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1/2 | CCC |
G 207 M.D. Anderson Cancer Center | Phase 1 | CC |
Oxodotreotide Sociedad Española de Medicina Nuclear e Imagen Molecular | D |
Same molecule, other indications
Dendritic Cell Tumor Fusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →